Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

An investigation of adverse effects caused by the injection of high-dose TNFα-expressing adenovirus vector into established murine melanoma

Gene Therapy volume 10, pages 700–705 (2003)Cite this article

Abstract

We previously reported that RGD fiber-mutant adenovirus vector carrying human TNFα cDNA (AdRGD-TNFα) could more effectively induce mouse B16 BL6 melanoma regression than conventional Ad-TNFα on intratumoral injection at less than 109 vector particles (VP). Although mice treated with either Ad type at 1010 VP showed remarkable tumor regression due to hemolytic necrosis, severe adverse effects including extreme reduction in body weight were also induced by Ad treatment. Here, we attempted to elucidate the cause of the adverse effects to optimize the application of AdRGD-TNFα. More than 99% of systemically administered Ad accumulated in the liver, and the rate of Ad leakage into systemic circulation from the B16 BL6 tumors injected with AdRGD or conventional Ad at 1010 VP was about 1% of the administered VP. Although the leaked Ad did not directly induce hepatotoxicity or body weight reduction, excessive TNFα produced in the tumors leaked into the blood at high concentrations and caused systemic inflammation, tissue denaturation, and body weight reduction in mice injected intratumorally with AdRGD-TNFα or Ad-TNFα at 1010 VP. Our results demonstrated that an exact AdRGD-TNFα dosage must be determined to prevent TNFα leakage from tumors into systemic circulation, thereby enabling safe application of AdRGD-TNFα to clinical melanoma gene therapy in the future.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Kay MA, Woo SL . Gene therapy for metabolic disorders. Trends Genet 1994; 10: 253–257.

    Article  CAS  PubMed  Google Scholar 

  2. Kozarsky KF, Wilson JM . Gene therapy: adenovirus vectors. Curr Opin Genet Dev 1993; 3: 499–503.

    Article  CAS  PubMed  Google Scholar 

  3. Hemmi S et al. The presence of human coxsackie virus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther 1998; 9: 2363–2373.

    Article  CAS  PubMed  Google Scholar 

  4. Okada Y et al. Fiber-mutant technique can augment gene transduction efficacy and anti-tumor effects against established murine melanoma by cytokine-gene therapy using adenovirus vectors. Cancer Lett 2002; 177: 57–63.

    Article  CAS  PubMed  Google Scholar 

  5. Okada Y et al. Tumor necrosis factor α-gene therapy for an established murine melanoma using RGD (Arg–Gly–Asp) fiber-mutant adenovirus vectors. Jpn J Cancer Res 2002; 93: 436–444.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Mizuguchi H et al. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther 2001; 8: 730–735.

    Article  CAS  PubMed  Google Scholar 

  7. Okada N et al. Efficient gene delivery into dendritic cells by fiber-mutant adenovirus vectors. Biochem Biophys Res Commun 2001; 282: 173–179.

    Article  CAS  PubMed  Google Scholar 

  8. Okada N et al. Efficient antigen gene transduction using Arg–Gly–Asp fiber-mutant adenovirus vectors can potentiate anti-tumor vaccine efficacy and maturation of murine dendritic cells. Cancer Res 2001; 61: 7913–7919.

    CAS  PubMed  Google Scholar 

  9. Toloza EM et al. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Ther 1996; 3: 11–17.

    CAS  PubMed  Google Scholar 

  10. Chapman PB et al. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol 1987; 5: 1942–1951.

    Article  CAS  PubMed  Google Scholar 

  11. Sherman ML et al. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. Clin Oncol 1988; 6: 344–350.

    Article  CAS  Google Scholar 

  12. Taguchi T . Phase I study of recombinant human tumor necrosis factor (rHu-TNF:PT-050). Cancer Detect Prev 1988; 12: 561–572.

    CAS  PubMed  Google Scholar 

  13. Yang Y, Ertl HC, Wilson JM . MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994; 1: 433–442.

    Article  CAS  PubMed  Google Scholar 

  14. Yang Y, Li Q, Ertl HC, Wilson JM . Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004–2015.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Yang Y, Wilson JM . Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo. J Immunol 1995; 155: 2564–2570.

    CAS  PubMed  Google Scholar 

  16. Bergelson JM et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320–1323.

    Article  CAS  PubMed  Google Scholar 

  17. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR . Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309–319.

    Article  CAS  PubMed  Google Scholar 

  18. Wickham TJ, Filardo EJ, Cheresh DA, Nemerow GR . Integrin αvβ5 selectively promotes adenovirus mediated cell membrane permeabilization. J Cell Biol 1994; 127: 257–264.

    Article  CAS  PubMed  Google Scholar 

  19. Mizuguchi H et al. CAR- or αv integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice. Gene Ther 2002; 9: 769–776.

    Article  CAS  PubMed  Google Scholar 

  20. Fechner H et al. Expression of coxsackie adenovirus receptor and αv-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther 1999; 9: 1520–1535.

    Article  Google Scholar 

  21. Alemany R, Suzuki K, Curiel DT . Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 2000; 81: 2605–2609.

    Article  CAS  PubMed  Google Scholar 

  22. De Leeuw AM, Brouwer A, Knook DL . Sinusoidal endothelial cells of the liver: fine structure and function in relation to age. J Electron Microsc Tech 1990; 14: 218–236.

    Article  CAS  PubMed  Google Scholar 

  23. Marr RA et al. Tumour therapy in mice using adenovirus vectors expressing human TNFα. Int J Oncol 1998; 12: 509–515.

    CAS  PubMed  Google Scholar 

  24. Kianmanesh A et al. Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor α together with naive dendritic cells elicits significant suppression of tumor growth without toxicity. Hum Gene Ther 2001; 12: 2035–2049.

    Article  CAS  PubMed  Google Scholar 

  25. Marr RA et al. Tumour immunotherapy using an adenovirus vector expressing a membrane-bound mutant of murine TNFα. Gene Ther 1997; 4: 1181–1188.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the Applied Medical Research Laboratory (Osaka, Japan) for technical assistance with HE staining, Yasushige Masunaga and Sayaka Iiyama (Kyoto Pharmaceutical University) for technical assistance with the RT-PCR analysis, and Makiko Kanehira and Naoko Nishino (Mukogawa Women's University) for assisting with the animal studies. The present study was supported in part by the Sasakawa Scientific Research Grant from The Japan Science Society, and by grants from the Ministry of Health and Welfare in Japan.

Author information

Authors and Affiliations

  1. Department of Pharmaceutics, School of Pharmaceutical Sciences, Mukogawa Women's University, Kyuban-cho, Koshien, Nishinomiya, Hyogo, Japan

    Y Okada & N Mizuno

  2. Department of Biopharmaceutics, Kyoto Pharmaceutical University, Misasagi, Yamashina-ku, Kyoto, Japan

    N Okada

  3. Division of Cellular and Gene Therapy Products, National Institute of Health Sciences, Kamiyoga, Setagaya-ku, Tokyo, Japan

    H Mizuguchi & T Hayakawa

  4. Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Osaka University, Yamadaoka, Suita, Osaka, Japan

    T Mayumi

Authors
  1. Y Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Mizuguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Hayakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Mayumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N Mizuno
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Okada, Y., Okada, N., Mizuguchi, H. et al. An investigation of adverse effects caused by the injection of high-dose TNFα-expressing adenovirus vector into established murine melanoma. Gene Ther 10, 700–705 (2003). https://doi.org/10.1038/sj.gt.3301876

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3301876

Keywords

This article is cited by

Search

Advanced search

Quick links